Race Oncology (RAC) - Managing Director and CEO, Phil Lynch (left)
Managing Director and CEO, Phil Lynch (left)
Source: Race Oncology
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • A second independent study has confirmed the inhibiting capabilities of Race Oncology’s (RAC) drug, Bisantrene
  • A research team at the University of Chicago demonstrated Bisantrene’s ability to inhibit the Fat Mass and Obesity associated protein (FTO)
  • This supports the City of Hope Hospital’s 2020 hypothesis that Bisantrene can inhibit the FTO involved in skin cancer development
  • This additional independent confirmation will help to progress Race Oncology’s clinical plans for Bisantrene 
  • Race Oncology is up 10.78 per cent and trading at $3.39 per share

A second independent study has confirmed the inhibiting capabilities of Race Oncology’s (RAC) drug, Bisantrene.

In 2020, Professor Chen and his team at the City of Hope Hospital identified Bisantrene as a potent inhibitor of the Fat Mass and Obesity-associated protein (FTO). The FTO is hypothesised to have a major role in the development of skin cancers, but the results from the City of Hope Hospital needed to be replicated in order for this potential discovery to be taken seriously.

There is currently a replication crisis in cancer research, meaning that many exciting potential discoveries have not been successfully repeated in independent laboratories. However, according to details in a recent scientific publication in the journal Nature Communication, an independent study has been able to support the theory about Bisantrene as an FTO inhibitor.

A research team at the University of Chicago, led by Professors Chuan He and Yu-Ying He, recently identified that the FTO plays a critical role in developing skin cancers caused by low-level arsenic exposure. The team was also able to demonstrate that Bisantrene-targeted inhibition of FTO limited the growth of these skin cancers, in both cell cultures and mice.

Race Oncology’s Chief Scientific Officer, Dr Daniel Tillett, commented that independent confirmation of Bisantrene’s ability to target FTO and treat skin cancer is of great importance.

“Many scientists and pharmaceutical companies are sceptical of potential cancer breakthroughs until they have been replicated by an independent group of researchers,” he said.

“This new paper repeating the earlier FTO work of the City of Hope Hospital is a major step forward for our clinical plans for Bisantrene,” he added.

Race Oncology is up 10.78 per cent, trading at $3.39 per share at 11:21 am AEST.

RAC by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…